Clinical Outcomes in Patients with Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Bloodstream Infection
about
Catheter-related bloodstream infection in end-stage kidney disease: a Canadian narrative reviewEvaluation of vancomycin population susceptibility analysis profile as a predictor of outcomes for patients with infective endocarditis due to methicillin-resistant Staphylococcus aureus.Impact of the combination of daptomycin and trimethoprim-sulfamethoxazole on clinical outcomes in methicillin-resistant Staphylococcus aureus infections.Association between vancomycin day 1 exposure profile and outcomes among patients with methicillin-resistant Staphylococcus aureus infective endocarditis.Clinical and microbiologic analysis of the risk factors for mortality in patients with heterogeneous vancomycin-intermediate Staphylococcus aureus bacteremia.Clinical outcomes and molecular typing of heterogenous vancomycin-intermediate Staphylococcus aureus bacteremia in patients in intensive care unitsHigh-dose daptomycin therapy for staphylococcal endocarditis and when to apply it.Rapid Detection of Vancomycin-Intermediate Staphylococcus aureus by Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry.Clinical and Microbiological Characteristics of Heteroresistant and Vancomycin-Intermediate Staphylococcus aureus from Bloodstream Infections in a Brazilian Teaching HospitalThe safety and efficacy of high versus low vancomycin trough levels in the treatment of patients with infections caused by methicillin-resistant Staphylococcus aureus: a meta-analysisHeteroresistant Vancomycin Intermediate Coagulase Negative Staphylococcus in the NICU: A Systematic Review.Pneumonia Caused by Methicillin-Resistant Staphylococcus aureus: Does Vancomycin Heteroresistance Matter?Sequential Evolution of Vancomycin-Intermediate Resistance Alters Virulence in Staphylococcus aureus: Pharmacokinetic/Pharmacodynamic Targets for Vancomycin Exposure.Vancomycin susceptibility in methicillin-resistant Staphylococcus aureus is mediated by YycHI activation of the WalRK essential two-component regulatory systemMulticenter Observational Study of Ceftaroline Fosamil for Methicillin-Resistant Staphylococcus aureus Bloodstream Infections.Large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy.Antimicrobial resistance: impact on clinical and economic outcomes and the need for new antimicrobials.Clinical implications of vancomycin heteroresistant and intermediately susceptible Staphylococcus aureus.Glycopeptide antibiotics: evolving resistance, pharmacology and adverse event profile.Relationship between day 1 and day 2 Vancomycin area under the curve values and emergence of heterogeneous Vancomycin-intermediate Staphylococcus aureus (hVISA) by Etest® macromethod among patients with MRSA bloodstream infections: a pilot studyImpact of Time to Appropriate Therapy on Mortality in Patients with Vancomycin-Intermediate Staphylococcus aureus Infection.Treatment of Staphylococcus aureus Infections.Pharmacist-managed dose adjustment feedback using therapeutic drug monitoring of vancomycin was useful for patients with methicillin-resistant Staphylococcus aureus infections: a single institution experience.Effect of teicoplanin on Staphylococcus aureus with heterointermediate susceptibility to glycopeptides in experimental infective endocarditis model.Antibiofilm and membrane-damaging potential of cuprous oxide nanoparticles against Staphylococcus aureus with reduced susceptibility to vancomycin.Combination of cephalosporins with vancomycin or teicoplanin enhances antibacterial effect of glycopeptides against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) and VISA.Outcomes of vancomycin plus a β-lactam versus vancomycin only for the treatment of methicillin-resistant Staphylococcus aureus bacteremia.Antimicrobial resistance and prevalence of CvfB, SEK and SEQ genes among Staphylococcus aureus isolates from paediatric patients with bloodstream infections.Rapid and easy detection of low-level resistance to vancomycin in methicillin-resistant Staphylococcus aureus by matrix-assisted laser desorption ionization time-of-flight mass spectrometry.Estimating the burden of antimicrobial resistance: a systematic literature review.
P2860
Q26751691-89D15B3A-2CDE-4FD6-A1E4-ECE911E2B6B0Q34058222-870E6D23-BC8F-42DE-8919-1C4BC026389AQ35169018-8DFB0920-9380-4D05-8727-BFC275D40855Q35607636-D181ABBB-D2E8-45EC-B6CF-97528C26796AQ35607912-EF75E4F6-E972-4D54-BCE2-F82E59FE49ABQ35819831-6E75346E-CF93-4AD1-8A57-79531AA6FC7BQ35848781-3A82477B-B839-4972-A7DD-24645C6F7949Q35893439-69DC28A8-82EB-4A42-B3DA-C062B1B5FD02Q36116970-60AF9394-72B3-48E5-B65B-CC550C098CE0Q36148828-657E9F30-AD9E-47CB-A797-93B741E0945EQ36157736-644E1005-A9F4-4992-B5EE-0298A8C52F00Q36644689-12AF18FD-15F0-42FE-9902-E749F5E412A9Q36644897-9310D021-2C87-4A5A-9CA0-253ADC852338Q37236231-11988758-8A9B-4FD2-AFED-98D4CF406B1DQ37613052-8F6D6675-1BC8-46A1-B85F-1BD2BD02198CQ37713010-EAAC81F4-C880-4857-9AEB-36D3C3DBB41AQ38286351-508F6E1D-077E-4880-8A66-919CA6FD4245Q38425879-DBB9D1C7-89F5-48F2-999D-F5272D0B17AAQ38545589-477AB35F-7B17-4491-8642-44F60097487EQ38648530-3A51F2AB-7559-477A-9F2A-6100B4B246E5Q38843037-6CD1A40F-E3F8-4503-A396-748C3B258BFFQ40049973-E72965E0-91B3-4DD3-AC0E-115180525485Q40478665-93B0F4E1-CE2B-4D0E-BF54-D07E083B9ACEQ41229114-717F92C1-BE94-4B0A-9FBA-336781535682Q41832910-EA6787BD-5D11-416D-B181-BB56FE44DB67Q41869403-7B4E63BF-FF6E-40EA-901E-690B6818D691Q46916150-06B3EC39-837A-40B1-ABDD-148277CF26D7Q50042502-68052890-52B3-420E-9F05-FCC2337B2DEDQ50420166-AB1A4613-5BC7-4567-83C4-059F70CFBD74Q53689673-DA7A2C73-4F4D-4F40-8707-C4737C783C85
P2860
Clinical Outcomes in Patients with Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Bloodstream Infection
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 24 June 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Clinical Outcomes in Patients ...... s aureus Bloodstream Infection
@en
Clinical Outcomes in Patients ...... aureus Bloodstream Infection.
@nl
type
label
Clinical Outcomes in Patients ...... s aureus Bloodstream Infection
@en
Clinical Outcomes in Patients ...... aureus Bloodstream Infection.
@nl
prefLabel
Clinical Outcomes in Patients ...... s aureus Bloodstream Infection
@en
Clinical Outcomes in Patients ...... aureus Bloodstream Infection.
@nl
P2093
P2860
P356
P1476
Clinical Outcomes in Patients ...... s aureus Bloodstream Infection
@en
P2093
Anthony M Casapao
Brian A Potoski
Debra A Goff
Kerry L LaPlante
Michael J Rybak
Nimish Patel
Steven N Leonard
Susan L Davis
Thomas P Lodise
P2860
P304
P356
10.1128/AAC.00380-13
P407
P577
2013-06-24T00:00:00Z